Quel est le prix pour Celltrion, Inc. (068270)

Le prix pour Celltrion, Inc. (068270) est $132.08

Quelle est la capitalisation boursière pour Celltrion, Inc. (068270)

La capitalisation boursière pour Celltrion, Inc. (068270) est $30.29B

Celltrion, Inc. (068270) Ratio P/S

Celltrion, Inc., a South Korean biopharmaceutical company, specializes in the development and manufacturing of protein-based therapies, including treatments for oncology. Its commercial portfolio features established products such as Remsima, Truxima, and Herzuma, alongside a range of generic pharmaceuticals and diagnostic kits for COVID-19. The company maintains an extensive pipeline of antibody biosimilars currently undergoing various stages of clinical evaluation. Late-stage (Phase 3) candidates include CT-P17, aimed at rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease (IBD); CT-P16, targeting metastatic colorectal and breast cancers; CT-P43, for inflammatory conditions like psoriasis, Crohn's disease, and ulcerative colitis; CT-P42, addressing diabetic macular edema; and CT-P59, developed for COVID-19. In Phase 2, CT-P27 is being tested for pandemic and seasonal influenza. Earlier in development, Phase 1 assets comprise CT-P39 for asthma and urticaria, CT-P41 for osteoporosis and bone loss, and CT-G20 for cardiomyopathy. Additionally, Celltrion maintains a collaboration with Inhalon Biopharma, Inc. to advance IN-006, an inhaled formulation of regdanvimab intended for the treatment of COVID-19 patients. Established in 2002, the company operates primarily from its headquarters in Incheon, South Korea.

Année	Ratio P/S	Changez
Pas assez de données pour les dates fournies.

Année

Ratio P/S

Changez

Pas assez de données pour les dates fournies.

Entreprise	Ratio P/S	Différence de Ratio P/S	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
CSL Limited CSL.AX	2.95	-	AU
Moderna, Inc. MRNA.US	11.28	-	US
Lonza Group AG LONN.SW	-	-	CH

Entreprise

Ratio P/S

Différence de Ratio P/S

Pays